Literature DB >> 23389085

Therapeutic strategies to improve control of hypertension.

Pedro Armario1, Bernard Waeber.   

Abstract

Blood pressure is poorly controlled in most European countries and the control rate is even lower in high-risk patients such as patients with chronic kidney disease, diabetic patients or previous coronary heart disease. Several factors have been associated with poor control, some of which involve the characteristic of the patients themselves, such as socioeconomic factors, or unsuitable life-styles, other factors related to hypertension or to associated comorbidity, but there are also factors directly associated with antihypertensive therapy, mainly involving adherence problems, therapeutic inertia and therapeutic strategies unsuited to difficult-to-control hypertensive patients. It is common knowledge that only 30% of hypertensive patients can be controlled using monotherapy; all the rest require a combination of two or more antihypertensive drugs, and this can be a barrier to good adherence and log-term persistence in patients who also often need to use other drugs, such as antidiabetic agents, statins or antiplatelet agents. The fixed combinations of three antihypertensive agents currently available can facilitate long-term control of these patients in clinical practice. If well tolerated, a long-term therapeutic regimen that includes a diuretic, an ACE inhibitor or an angiotensin receptor blocker, and a calcium channel blocker is the recommended optimal triple therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389085     DOI: 10.1097/HJH.0b013e32835d2c6c

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  8 in total

1.  Predicting changes in hypertension control using electronic health records from a chronic disease management program.

Authors:  Jimeng Sun; Candace D McNaughton; Ping Zhang; Adam Perer; Aris Gkoulalas-Divanis; Joshua C Denny; Jacqueline Kirby; Thomas Lasko; Alexander Saip; Bradley A Malin
Journal:  J Am Med Inform Assoc       Date:  2013-09-17       Impact factor: 4.497

2.  Risk Factors for Low Pharmacy Refill Adherence Among Older Hypertensive Men and Women by Race.

Authors:  LaKeisha G Williams; Erin Peacock; Cara Joyce; Lydia A Bazzano; Daniel Sarpong; Paul K Whelton; Elizabeth W Holt; Richard Re; Edward Frohlich; Jiang He; Paul Muntner; Marie Krousel-Wood
Journal:  Am J Med Sci       Date:  2018-07-29       Impact factor: 2.378

3.  Utilization of antihypertensive drugs among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C-STRIDE).

Authors:  Bianling Liu; Qin Wang; Yu Wang; Jinwei Wang; Luxia Zhang; Minghui Zhao
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-09       Impact factor: 3.738

4.  Patient and physician adherence in hypertension management.

Authors:  J Rick Turner
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-11       Impact factor: 3.738

5.  Effects on hypertensive patients' satisfaction with information about their medication after nurses' consultation training.

Authors:  Eva Drevenhorn; Ann Bengtson; Per Nyberg; Karin I Kjellgren
Journal:  Pragmat Obs Res       Date:  2014-10-01

6.  Factors influencing adherence to treatment in older adults with hypertension.

Authors:  Bartosz Uchmanowicz; Anna Chudiak; Izabella Uchmanowicz; Joanna Rosińczuk; Erika Sivarajan Froelicher
Journal:  Clin Interv Aging       Date:  2018-11-28       Impact factor: 4.458

Review 7.  Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease.

Authors:  Ying Shen; Yang Dai; Xiao Qun Wang; Rui Yan Zhang; Lin Lu; Feng Hua Ding; Wei Feng Shen
Journal:  Cardiovasc Diabetol       Date:  2019-11-16       Impact factor: 9.951

8.  Impact Of Hypertension versus Diabetes on Cardiovascular and All-cause Mortality in Iranian Older Adults: Results of 14 Years of Follow-up.

Authors:  Neda Zafari; Samaneh Asgari; Mojtaba Lotfaliany; Amirreza Hadaegh; Fereidoun Azizi; Farzad Hadaegh
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.